High circulating VEGF level predicts poor overall survival in lung cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 7, 2013, Pages 1157-1167

  Hu, Pingping ^a   Liu, Weidong ^b   Wang, Liguang ^a   Yang, Miaomiao ^a   Du, Jiajun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG MEDICAL IMAGING RESEARCH INSTITUTE   (China)

Author keywords

Circulating vascular endothelial growth factor; Lung cancer; Prognosis; Survival

Indexed keywords

VASCULOTROPIN;

ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INOPERABLE CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SURGERY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879213667     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1425-1     Document Type: Article

References (54)

1. Altman DG (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323(7306):224-228
2. An SJ, Huang YS, Chen ZH, Su J, Yang Y, Chen JG, Yan HH, Lin QX, Yang JJ, Yang XN, Zhou Q, Zhang XC, Wu YL (2012) Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Med Oncol 29(2):627-632. doi: 10.1007/s12032-011-9924-x
3. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410 (Pubitemid 37328844)
4. Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G (1998) Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 18(2A):1123-1127 (Pubitemid 28239651)
5. Brattstrom D, Bergqvist M, Hesselius P, Larsson A, Lamberg K, Wernlund J, Brodin O, Wagenius G (2002) Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 37(1):57-63 (Pubitemid 34621459)
6. Carrillo-de Santa Pau E, Carrillo Arias F, Caso Pelaez E, Muguruza Trueba I, Sanchez Hernandez I, Munoz Molina GM, Moreno Balsalobre R, Sacristan Lopez S, Gomez-Pinillos A, Toledo Lobo Mdel V (2010) Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest 28(4):393-398. doi: 10.3109/07357900903405900
7. Chakra M, Pujol JL, Lamy PJ, Bozonnat MC, Quantin X, Jacot W, Daures JP (2008) Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol 3(10):1119-1126. doi: 10.1097/JTO.0b013e318187464e
8. Choi JH, Kim HC, Lim HY, Nam DK, Kim HS, Yi JW, Chun M, Oh YT, Kang S, Park KJ, Hwang SC, Lee YH, Hahn MH (2001) Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer 33(2-3):171-179 (Pubitemid 32707898)
9. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere J, Benamouzig R, Breau J, Perret G (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94(12):1823-1832 (Pubitemid 43882572)
10. Donovan L, Sankaridurg P, Ho A, Naduvilath T, Smith EL III, Holden BA (2012) Myopia progression rates in urban children wearing single-vision spectacles. Optom Vis Sci 89(1):27-32. doi: 10.1097/OPX.0b013e3182357f79
11. Dudek AZ, Mahaseth H (2005) Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 23(3):193-200 (Pubitemid 40770736)
12. Edelman MJ, Hodgson L, Wang XF, Christenson R, Jewell S, Vokes E, Kratzke R (2011) Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: cancer and leukemia group B 150304. J Thorac Oncol 6(11):1902-1906. doi: 10.1097/JTO.0b013e31822a7383
13. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G (1997) Language bias in randomised controlled trials published in English and German. Lancet 350(9074):326 (Pubitemid 27351115)
14. Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS, Awada AH, Shamseddine A (2012) Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol 84(2):149-160. doi: 10.1016/j.critrevonc.2012.02.012
15. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676 (Pubitemid 36749215)
16. Firat S, Bousamra M, Gore E, Byhardt RW (2002) Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52(4):1047 (Pubitemid 34219026)
17. Folkman J, Kalluri R (2004) Cancer without disease. Nature 427(6977):787 (Pubitemid 38297724)
18. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV (2009) Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-3609. doi: 10.1158/1078-0432.CCR-08-2568
19. Hasegawa Y, Takanashi S, Okudera K, Kumagai M, Hayashi A, Morimoto T, Okumura K (2005) Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients. Intern Med 44(1):26-34 (Pubitemid 40260037)
20. Hegde PS, Jubb AM, Chen D, Li NF, Meng G, Bernaards C, Elliott R, Scherer S, Chen DS (2012) Predictive impact of circulating vascular endothelial growth factor in 4 phase III trials evaluating bevacizumab. Clin Cancer Res. doi: 10.1158/1078-0432.ccr-12-2535
21. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K (1998) Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115(5):1007-1014 (Pubitemid 28224393)
22. Jantus-Lewintre E, Sanmartin E, Sirera R, Blasco A, Sanchez JJ, Taron M, Rosell R, Camps C (2011) Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer 74(2):326-331. doi: 10.1016/j.lungcan.2011.02.016
23. Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47(4):617-623 (Pubitemid 32275802)
24. Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q (2012) ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 39(6):6933-6942. doi: 10.1007/s11033-012- 1520-4
25. Kaya A, Ciledag A, Gulbay BE, Poyraz BM, Celik G, Sen E, Savas H, Savas I (2004) The prognostic significance of vascular endothelial growth factor levees in sera of non-small cell lung cancer patients. Respir Med 98(7):632-636. doi: 10.1016/j.rmed.2003.12.017 (Pubitemid 38949927)
26. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H (1994) Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1221(2):211-214 (Pubitemid 24103822)
27. Kut C, Mac Gabhann F, Popel AS (2007) Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97(7):978-985. doi: 10.1038/sj.bjc.6603923 (Pubitemid 47519292)
28. Kyzas PA, Cunha IW, Ioannidis JPA (2005) Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 11(4):1434-1440 (Pubitemid 40315223)
29. Laack E, Scheffler A, Burkholder I, Boeters I, Andritzky B, Schuch G, Gorn M, Vohwinkel G, Edler L, Fiedler W, Hossfeld DK (2005) Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 50(1):51-58. doi: 10.1016/j.lungcan.2005.05.011 (Pubitemid 41297469)
30. Lakatos E (1988) Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 44(1):229-241 (Pubitemid 18098824)
31. Lakatos E (2002) Designing complex group sequential survival trials. Stat Med 21(14):1969-1989 (Pubitemid 34752618)
32. Leal YA, Cedillo-Rivera R, Simon JA, Velazquez JR, Flores LL, Torres J (2011) Utility of stool sample-based tests for the diagnosis of Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 52(6):718-728. doi: 10.1097/MPG.0b013e3182077d33
33. Lee J, Hong Y, Han C, Hwang D, Hong S (2000) Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol 17(1):149-152
34. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR (2008) Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26(29):4771-4776. doi: 10.1200/JCO.2008.17.0662
35. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, Lafitte JJ, Sculier JP (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92(1):131-139. doi: 10.1038/sj.bjc.6602258 (Pubitemid 40188446)
36. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P et al (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13(5):1221-1230
37. Qin L, Bromberg-White J, Qian C (2012) Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed. Adv Cancer Res 113:191
38. Qu JT, Wang M, He HL, Tang Y, Ye XJ (2012) The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Can Res Clin Oncol 138(5):819-825
39. Sakurai T, Kudo M (2011) Signaling pathways governing tumor angiogenesis. Oncology 81(Suppl 1):24-29. doi: 10.1159/000333256
40. Salven P, Ruotsalainen T, Mattson K, Joensuu H (1998) High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79(2):144-146 (Pubitemid 28201685)
41. Schoenleber S, Kurtz D, Talwalkar J, Roberts L, Gores G (2009) Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100(9):1385-1392
42. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983-985
43. Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H, Fukurchi Y (2005) Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 183(1):29-42. doi: 10.1007/s00408-004-2521-4 (Pubitemid 41264745)
44. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10-29. doi: 10.3322/caac.20138
45. Smith R, Tang J, Tudur-Smith C, Neoptolemos J, Ghaneh P (2011) Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 104(9):1440-1451
46. Sorenson S, Fohlin H, Lindgren A, Lindskog M, Bergman B, Sederholm C, Ek L, Lamberg K, Clinchy B (2012) Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy. Eur J Cancer. doi: 10.1016/j.ejca.2012.07.032
47. Stewart L, Parmar M (1993) Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341(8842):418-422 (Pubitemid 23048157)
48. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E (2006) Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 24(6):576-580. doi: 10.1080/07357900600894781 (Pubitemid 44422920)
49. Thurston G, Kitajewski J (2008) VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 99(8):1204-1209
50. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(1):16 (Pubitemid 47161711)
51. Tonini C, Beghi E, Berg AT, Bogliun G, Giordano L, Newton RW, Tetto A, Vitelli E, Vitezic D, Wiebe S (2004) Predictors of epilepsy surgery outcome: a meta-analysis. Epilepsy Res 62(1):75 (Pubitemid 39424193)
52. Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G (2011) Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 41(1):1-11. doi: 10.1016/j.semarthrit.2010. 08.001
53. Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ (2012) Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Br J Cancer 106(6):1153-1159. doi: 10.1038/bjc.2012.50
54. Zhan P, Wang J, Lv X, Wang Q, Qiu L, Lin X, Yu L, Song Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4(9):1094 Shandong